A Note Before We Start
The peer-reviewed literature on cannabiorcol — the methyl-side-chain homolog of cannabinol, abbreviated CBN-C1 — is extremely thin. There are no published clinical trials, no in vivo animal pharmacology studies, and only a handful of phytochemistry papers that report its presence in cannabis material at trace levels. This article will be honest about that, and will avoid extrapolating from related cannabinoids.
A second clarification matters here. The literature uses several closely related names that should not be confused:
- Cannabiorcol = the orcinoid (1-carbon methyl side chain) homolog of cannabinol (CBN), abbreviated CBN-C1.
- Cannabidiorcol = the orcinoid homolog of cannabidiol (CBD), abbreviated CBD-C1.
- Tetrahydrocannabiorcol = the orcinoid homolog of THC, abbreviated THC-C1.
These are distinct compounds with distinct (and almost entirely uncharacterized) pharmacology. This article is about CBN-C1, the cannabinol-family orcinoid.
What Is CBN-C1?
Cannabiorcol (CBN-C1) is a minor cannabinoid found in Cannabis sativa. Structurally, it shares the fully aromatized cannabinol core but carries a one-carbon (methyl) alkyl side chain in place of cannabinol’s five-carbon (pentyl) chain. Compounds with one-carbon side chains in the cannabinoid family are referred to as orcinoids, derived from “orcinol,” the 5-methylresorcinol building block in their biosynthetic pathway (Hanuš et al., 2016).
Like other CBN-type cannabinoids, CBN-C1 is non-intoxicating in the published literature. It is found at very low concentrations in cannabis flower and is generally considered an end-state oxidation product within the orcinoid branch of the cannabinoid pathway (Maioli et al., 2022).
Where CBN-C1 Comes From
The orcinoid cannabinoid pathway parallels the pentyl pathway that produces the major cannabinoids (CBG, CBD, THC, CBN, etc.), but with a different polyketide starter unit:
1. Instead of the fatty-acid–derived olivetolic acid (pentyl) used in the production of CBGA, the orcinoid pathway uses orsellinic acid or its analog as the polyketide starter. 2. A prenyltransferase enzyme adds geranyl pyrophosphate to that orcinoid starter, producing the orcinoid analog of CBGA — sometimes called CBGA-C1 or cannabigerorcinic acid. 3. Downstream enzymes (or, in the case of the CBN line, slow oxidative aromatization) generate the orcinoid analogs of THCA, CBDA, CBCA, and ultimately CBN-C1 (Hanuš et al., 2016; Luo et al., 2019).
CBN-C1 specifically is best understood as the orcinoid counterpart of CBN — that is, the fully aromatized, oxidation-end product of the orcinoid analog of THC.
Pharmacology: Where the Literature Is Thin
The honest summary: there is no detailed pharmacological characterization of CBN-C1 in the peer-reviewed literature. As of the time of writing:
- No published in vivo studies have specifically tested CBN-C1 in animal models.
- No clinical trials have been conducted in humans.
- No detailed receptor- or channel-binding panels have been published for CBN-C1. Affinity values for CB1, CB2, TRP channels, PPARs, and other targets — which have been mapped for CBN — have not been characterized for CBN-C1.
- No pharmacokinetic data have been published.
What is known is general and indirect. Side-chain length has a substantial effect on cannabinoid receptor binding: studies of THC analogs with different alkyl chain lengths have shown that shortening the side chain dramatically reduces CB1 affinity (Bow & Rimoldi, 2016). On that basis, CBN-C1 is unlikely to bind cannabinoid receptors strongly. But “unlikely on theoretical grounds” is not the same as “directly measured,” and consumers should not assume that CBN-C1 either does or does not produce a particular physiological effect — the relevant studies simply have not been done.
Why CBN-C1 Still Matters
Despite the lack of pharmacology data, CBN-C1 has practical research value:
Chemotaxonomy. The orcinoid cannabinoids — including CBN-C1, CBD-C1 (cannabidiorcol), and THC-C1 (tetrahydrocannabiorcol) — are diagnostic markers for some cannabis chemovars. Detection of these short-side-chain cannabinoids in expanded analytical panels can help phytochemists identify specific genetic lineages (Hanuš et al., 2016).
Reference standards. CBN-C1 is sold as a high-purity reference compound for HPLC and mass-spectrometry method development. This allows analytical labs to confidently identify the compound in plant extracts.
Synthetic chemistry. As medicinal-chemistry interest in modifying the cannabinoid scaffold continues, the orcinoid cannabinoids represent the extreme low end of the side-chain-length series — useful as data points for understanding how alkyl chain length affects pharmacology.
Safety and Regulatory Status
There are no published clinical safety data on CBN-C1. The compound is not separately scheduled in most jurisdictions, but is generally regulated under the broader cannabis-derived cannabinoid framework wherever cannabis is regulated. The U.S. Food and Drug Administration has not approved CBN-C1 for any therapeutic indication.
Because no controlled human exposure data exist, CBN-C1–containing products should not be used by people who are pregnant, nursing, taking prescription medications, or managing a medical condition. Anyone considering products that list CBN-C1 among their cannabinoids should ask the manufacturer for a verified Certificate of Analysis and discuss use with a qualified medical professional.
Frequently Asked Questions
Is CBN-C1 the same as CBN?
No. CBN has a five-carbon (pentyl) side chain; CBN-C1 has a one-carbon (methyl) side chain. They share the same aromatized cannabinoid core but differ in alkyl chain length, and that difference is generally expected to substantially weaken cannabinoid receptor binding (Bow & Rimoldi, 2016).
Is CBN-C1 the same as cannabidiorcol?
No. Cannabiorcol (CBN-C1) is the orcinoid form of cannabinol. Cannabidiorcol (CBD-C1, also called CBDO) is the orcinoid form of cannabidiol. They are distinct compounds in distinct branches of the cannabinoid family.
Does CBN-C1 cause intoxication?
No published study has reported intoxicating effects from CBN-C1. In the absence of human data, this should be treated as an absence of evidence rather than evidence of safety.
Why is there so little research on CBN-C1?
Two practical reasons. First, CBN-C1 occurs in extremely low concentrations in cannabis, making isolation costly and time-consuming. Second, research funding has focused on the major cannabinoids — THC, CBD, and to a lesser extent CBG, CBN, and CBC — leaving rare orcinoid cannabinoids like CBN-C1 essentially unstudied.
References
Bow, E. W., & Rimoldi, J. M. (2016). The structure–function relationships of classical cannabinoids: CB1/CB2 modulation. Perspectives in Medicinal Chemistry, 8, 17–39. https://doi.org/10.4137/PMC.S32171
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016). Phytocannabinoids: A unified critical inventory. Natural Product Reports, 33(12), 1357–1392. https://doi.org/10.1039/C6NP00074F
Luo, X., Reiter, M. A., d’Espaux, L., Wong, J., Denby, C. M., Lechner, A., Zhang, Y., Grzybowski, A. T., Harth, S., Lin, W., Lee, H., Yu, C., Shin, J., Deng, K., Benites, V. T., Wang, G., Baidoo, E. E. K., Chen, Y., Dev, I., … Keasling, J. D. (2019). Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. Nature, 567(7746), 123–126. https://doi.org/10.1038/s41586-019-0978-9
Maioli, C., Mattoteia, D., Amin, H. I. M., Minassi, A., & Caprioglio, D. (2022). Cannabinol: History, syntheses, and biological profile of the greatest “minor” cannabinoid. Plants, 11(21), 2896. https://doi.org/10.3390/plants11212896
